Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
NEW YORK and MELBOURNE, Australia, Nov. 09, 2016 -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced it will report financial results for the first quarter ended September 30, 2016 and provide a corporate update beginning at 5:00 pm Eastern Time on Monday, November 14, 2016 and 9:00 am Australian Eastern Daylight Time on Tuesday, November 15, 2016.
To access the call, dial 1 855 881 1339 (toll-free US), 1 800 558 698 (toll-free Australia) or +61 2 9007 3187 (outside of the US and Australia).
The conference identification code is 912575.
The live webcast can be accessed via: http://webcasting.boardroom.media/broadcast/58214386d5f1311b35bd36a6
The conference call will be accompanied by a slide presentation. Please log in approximately 15 minutes prior to the scheduled start time.
The archived webcast will be available in the Events and Presentations section of the Investor page on the Company’s website – www.mesoblast.com
About Mesoblast
Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular diseases, immune-mediated and inflammatory disorders, orthopedic disorders, and oncologic/hematologic conditions.
For further information, please contact: Julie Meldrum Global Head, Corporate Communications Mesoblast Limited T: +61 3 9639 6036 E: [email protected] Schond Greenway VP, Investor Relations Mesoblast Limited T: +1 212 880-2060 E: [email protected]
